Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: A Phase II pilot study

Eric H Jensen, Leonard Armstrong, Chung K Lee, Todd M Tuttle, Selwyn M. Vickers, Timothy Sielaff, Edward W Greeno

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalHPB
Volume16
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Dive into the research topics of 'Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: A Phase II pilot study'. Together they form a unique fingerprint.

Cite this